
|Articles|August 29, 2022
Daily Medication Pearl: Meropenem IV
Author(s)Saro Arakelians, PharmD
Meropenem IV is an antibacterial medication indicated for the treatment of complicated stomach and skin structure infections.
Advertisement
Medication Pearl of the Day: Meropenem IV
Indication: Meropenem IV is an antibacterial medication indicated for the treatment of complicated stomach and skin structure bacterial infections in adult and pediatric patients 3 months of age and older; complicated intra-abdominal infections in adult and pediatric patients; and bacterial meningitis in patients 3 months of age and older.
Insight:
- Dosing: 500 mg every 8 hours by intravenous infusion over 15 to 30 minutes for complicated skin and skin structure infections (cSSSI) for adult patients. When treating infections caused by Pseudomonas aeruginosa, a dose of 1 gram every 8 hours is recommended.
- Dosage forms: 500 mg meropenem for injection vial (3) 1-gram meropenem for injection vial.
- Adverse events: Most common adverse reactions (2% or less) are headache, nausea, constipation, diarrhea, anemia, vomiting, and rash.
- Mechanism of action: Meropenem penetrates the cell wall of most gram-positive and gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Meropenem binds to PBPs 2, 3, and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2, and 4 of Staphylococcus aureus. Bactericidal concentrations (defined as a 3 log10 reduction in cell counts within 12 hours to 24 hours) are typically 1-2 times the bacteriostatic concentrations of meropenem, with the exception of Listeria monocytogenes, against which lethal activity is not observed.
Source:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First OTC Acetaminophen-Naproxen Combination for 12-Hour Pain Relief
2
Vaccine Guidance Is Rapidly Changing—Here's What You Need to Know
3
FDA Approves SimpleScreen CRC Blood Test for Colorectal Cancer Screening
4
Beyond Off-Label: How Auvelity's Approval Changes Agitation Management in Alzheimer Disease
5











































































































